Globally renowned expertise

R&D: targeted therapeutic response

Cancer research is one of our Group's priorities, with programs focusing particularly on targeted biotherapies. We work in fields where there the medical expectations are extremely high: solid tumors (breast, lung, colon, ovarian, bladder, and ENT cancers), onco-hematology (leukemia, myeloma, bone marrow transplants), and onco-dermatology, applying our four areas of expertise, namely new chemical entities, natural substances, biotherapies, and immunotherapy.

In oncology, we focus on indications that are still awaiting targeted treatment responses, while seeking to move away from currently available treatments, and we prioritize the development of new biological entities. We are renowned for our scientific expertise in monoclonal antibodies and immunoconjugates, which enables us to contribute to the revolution underway in targeted biotherapies", explains Frédéric Duchesne, CEO Pharmaceuticals Division.

Learn more about our cancer research


Focus on...biotherapies

Monoclonal antibodies are substances that can recognize the specific antigens expressed by cancer cells and bind to them. We can use monoclonal antibodies on their own (naked mAb) or join them to other substances (conjugated mAb). They are produced in a laboratory. Thanks to its targeted strategic partnerships and the creation of its special Immunology Center (the CIPF), the Group has become globally renowned for its expertise in the development of monoclonal antibodies.


Immunoconjugates are molecules that combine a protein (naturally produced by the body) and a cytotoxic agent (synthetic or plant-based). They are used to deliver active ingredients to the very core of a cancer cell, without affecting the surrounding healthy tissue.

 

Production: renowned cutting-edge manufacturing sites

Located in Gaillac and Pau, our manufacturing plants for oncology products are certified by the American, European, and Japanese pharmaceutical agencies (FDA, EMA, and PMDA). They handle all stages of the manufacturing process for producing either active ingredients or highly toxic cancer drugs.

In addition to working for the Group, these two plants make their expertise and technology available to other companies and manufacture active ingredients and cancer drugs on behalf of major international laboratories

  • Gaillac (Tarn): active ingredients
  • Pau (Pyrénées-Atlantiques): formulation and packaging